ERBB2 and breast carcinoma: Considering the faster growth of ErbB2-induced breast carcinomas in response to carbonic anhydrase inhibition (Fig. 8B) and the positive predictive value of carbonic anhydrases in HER2-enriched breast cancer (Fig. 3C, G), the current study does not support use of carbonic anhydrase inhibitors for treatment of HER2-enriched breast cancer.